Analysis

Pyxis Oncology, Inc. (PYXS) Stock Analysis

Pyxis Oncology, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to PYXS.

websitePYXS/analysis/PYXS

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to PYXS.

Stock profile

Ticker

PYXS

Asset type

Stock

Market cap

$128.6M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Pyxis Oncology, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • PYXS primary listing

Latest Pyxis Oncology, Inc. news

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, to...

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with ...

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-...

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, t...

Research sections

Valuation

Review valuation context for Pyxis Oncology, Inc..

Future growth

Review future growth context for Pyxis Oncology, Inc..

Past performance

Review past performance context for Pyxis Oncology, Inc..

Financial health

Review financial health context for Pyxis Oncology, Inc..

Dividend

Review dividend context for Pyxis Oncology, Inc..

Management

Review management context for Pyxis Oncology, Inc..

Ownership

Review ownership context for Pyxis Oncology, Inc..

Other information

Review other information context for Pyxis Oncology, Inc..

Community

Review community context for Pyxis Oncology, Inc..